US · DNA · BIOTECHNOLOGY
Ginkgo Bioworks Holdings, Inc. (DNA) intrinsic value and stock valuation
$7.46as of 2026-11-21 · Mkt cap 612.09M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ginkgo Bioworks Holdings, Inc. DCF and intrinsic value
InvestorsCraft values DNA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from DNA’s statements →
Ginkgo Bioworks Holdings, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- MBX Biosciences, Inc. Common Stock (MBX) $49.55
- Iovance Biotherapeutics, Inc. (IOVA) $6.90
- Vir Biotechnology, Inc. (VIR) $8.39
- ArriVent BioPharma, Inc. (AVBP) $10.52
- MeiraGTx Holdings plc (MGTX) $7.98
- Replimune Group, Inc. (REPL) $19.07
- Maravai LifeSciences Holdings, Inc. (MRVI) $6.98
- Arvinas, Inc. (ARVN) $6.46
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227M | $251.5M | $477.7M | $313.8M |
| Operating income | -$-315.28M | -$-559.76M | -$-864.41M | -$-2.21B | -$-1.83B |
| Net income | -$-312.76M | -$-547.03M | -$-892.87M | -$-2.1B | -$-1.83B |
| EPSd | -$-5.64M | -$-10.54M | -$-18.37M | -$-50.12M | -$-53.81M |
| Operating cash flow | -$-171.06M | -$-319.58M | -$-295.5M | -$-252.2M | -$-253.82M |
| Capital expenditure | -$-7.67M | -$-62.54M | -$-40.8M | -$-52.27M | -$-56.52M |
| Free cash flow | -$-178.72M | -$-382.13M | -$-336.3M | -$-304.47M | -$-310.34M |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B |
| Total debt | $439.9M | $467.7M | $239.3M | $442.6M | $23M |
| Net debt | $272.7M | -$-93.84M | -$-704.76M | -$-873.2M | -$-1.53B |
| Total equity | $508.6M | $716.1M | $1.1B | $1.74B | $1.57B |
| Cash and short-term investments | $422.6M | $561.6M | $944.1M | $1.32B | $1.55B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $170.2M | $227M | $251.5M | $477.7M | $313.8M |
| Cost of revenue | $31.5M | $38.6M | $54M | $204.2M | $129.7M |
| Gross profit | $138.6M | $188.5M | $197.5M | $273.5M | $184.2M |
| Research and development expenses | $243.8M | $424.1M | $580.6M | $1.05B | $1.15B |
| Selling, general and administrative expenses | $183.3M | $246.2M | $385M | $1.43B | $863M |
| Other expenses | $26.9M | $78M | $96.2M | $0.00 | $0.00 |
| Operating expenses | $453.9M | $748.3M | $1.06B | $2.48B | $2.01B |
| Cost and expenses | $485.4M | $786.8M | $1.12B | $2.69B | $2.14B |
| Interest income | $22.6M | $38.6M | $57.2M | $20.3M | $840K |
| Interest expense | $0.00 | $90K | $90K | $110K | $2.37M |
| Depreciation and amortization | $59M | $63M | $71.6M | $61.6M | $29.1M |
| Ebitda | -$-254.61M | -$-484.39M | -$-821.29M | -$-2.06B | -$-1.81B |
| Operating income | -$-315.28M | -$-559.76M | -$-864.41M | -$-2.21B | -$-1.83B |
| Total other income/expenses, net | $1.68M | $12.3M | -$-28.53M | $87.6M | -$-9.65M |
| Income before tax | -$-313.6M | -$-547.51M | -$-892.94M | -$-2.12B | -$-1.84B |
| Income tax expense | -$-840K | -$-480K | -$-70K | -$-15.03M | -$-1.48M |
| Net income | -$-312.76M | -$-547.03M | -$-892.87M | -$-2.1B | -$-1.83B |
| Weighted average shares outstanding | $55.5M | $51.9M | $48.5M | $41.9M | $33M |
| Weighted average diluted shares outstanding | $55.5M | $51.9M | $48.6M | $42M | $34M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $422.6M | $561.6M | $944.1M | $1.32B | $1.55B |
| Net receivables | $24M | $22.4M | $17.9M | $84M | $149.9M |
| Inventory | $0.00 | $0.00 | $50K | $4.36M | $3.36M |
| Total current assets | $471.8M | $602.7M | $1B | $1.45B | $1.72B |
| Property, plant and equipment, net | $528.7M | $598.2M | $395M | $718.8M | $145.8M |
| Goodwill and intangible assets | $56.9M | $72.5M | $132M | $171.3M | $43M |
| Long-term investments | $15.1M | $48.7M | $77.9M | $111.8M | $115.2M |
| Total non-current assets | $647.9M | $774.7M | $663.6M | $1.09B | $347.9M |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | $2.07B |
| Accounts payable | $10.6M | $14.2M | $9.32M | $10.5M | $8.19M |
| Short-term debt | $22.8M | $29M | $17.5M | $29.3M | $750K |
| Deferred revenue | $20M | $30.6M | $48.5M | $47.8M | $33.2M |
| Total current liabilities | $96M | $107.3M | $163.9M | $173M | $134.8M |
| Long-term debt | $417.1M | $438.8M | $221.8M | $413.3M | $22.3M |
| Deferred revenue, non-current | $75.2M | $98.8M | $158.1M | $174.8M | $156M |
| Total non-current liabilities | $515.1M | $554.1M | $404.3M | $630.1M | $368.9M |
| Capital lease obligations | $439.9M | $467.7M | $239.3M | $442.6M | $23M |
| Total liabilities | $611.1M | $661.4M | $568.2M | $803M | $503.6M |
| Common stock | $10K | $10K | $10K | $190K | $160K |
| Retained earnings | -$-6.15B | -$-5.84B | -$-5.29B | -$-4.4B | -$-2.3B |
| Accumulated other comprehensive income (loss) | $1.85M | -$-1.81M | $1.48M | -$-2.63M | -$-1.72M |
| Total equity | $508.6M | $716.1M | $1.1B | $1.74B | $1.57B |
| Total investments | $270.5M | $48.7M | $77.9M | $111.8M | $115.2M |
| Total debt | $439.9M | $467.7M | $239.3M | $442.6M | $23M |
| Net debt | $272.7M | -$-93.84M | -$-704.76M | -$-873.2M | -$-1.53B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-312.76M | -$-547.03M | -$-892.87M | -$-2.11B | -$-1.84B |
| Depreciation and amortization | $59M | $63M | $71.6M | $42.6M | $29.1M |
| Stock-based compensation | $81.6M | $112.3M | $229.9M | $1.93B | $1.61B |
| Change in working capital | -$-44.09M | -$-89.67M | $29.8M | -$-37.01M | -$-61.54M |
| Accounts receivable | -$-1.47M | -$-4.72M | $50.1M | $55M | -$-114.09M |
| Inventory | $0.00 | $0.00 | $0.00 | $160K | -$-630K |
| Accounts payable | -$-2.99M | $4.77M | -$-1.18M | -$-10.84M | -$-2.25M |
| Net cash provided by operating activities | -$-171.06M | -$-319.58M | -$-295.5M | -$-252.2M | -$-253.82M |
| Investments in property, plant and equipment | -$-7.67M | -$-62.54M | -$-40.8M | -$-52.27M | -$-56.52M |
| Acquisitions, net | $0.00 | -$-5.4M | -$-38.55M | $26.7M | -$-12.04M |
| Net cash used for investing activities | -$-240.29M | -$-62.24M | -$-80.69M | -$-67.39M | -$-73.26M |
| Common stock issued | $19.5M | $80K | $0.00 | $99.3M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | -$-20K | $0.00 | -$-25M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $17.8M | -$-1.74M | -$-3.22M | $95.3M | $1.53B |
| Net change in cash | -$-393.18M | -$-383.84M | -$-380M | -$-223.35M | $1.21B |
| Cash at end of period | $174.2M | $605.7M | $989.6M | $1.37B | $1.59B |
| Operating cash flow | -$-171.06M | -$-319.58M | -$-295.5M | -$-252.2M | -$-253.82M |
| Capital expenditure | -$-7.67M | -$-62.54M | -$-40.8M | -$-52.27M | -$-56.52M |
| Free cash flow | -$-178.72M | -$-382.13M | -$-336.3M | -$-304.47M | -$-310.34M |
Line items
Line items
Line items
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- CEO
- Jason Kelly
- Employees
- 485
- Beta
- 1.78
Explore
Frequently asked questions
What is the intrinsic value of Ginkgo Bioworks Holdings, Inc. (DNA)?
Ginkgo Bioworks Holdings, Inc. (DNA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is DNA undervalued?
DNA trades at a price of $7.46 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.